Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AZRX

AzurRx BioPharma (AZRX) Stock Price, News & Analysis

AzurRx BioPharma logo

About AzurRx BioPharma Stock (NASDAQ:AZRX)

Advanced Chart

Key Stats

Today's Range
$1.73
$2.15
50-Day Range
$2.40
$41.00
52-Week Range
$3.36
$26.30
Volume
274,361 shs
Average Volume
628,703 shs
Market Capitalization
$20.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive AZRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AzurRx BioPharma and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AZRX Stock News Headlines

Entero Therapeutics Inc (ENTO)
YS YS Biopharma Co., Ltd.
Altucher: It Looks Like My Trump prediction is coming true
New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.tc pixel
FWBI First Wave BioPharma, Inc.
First Wave BioPharma Inc (FWBI)
First Wave BioPharma Inc
See More Headlines

AZRX Stock Analysis - Frequently Asked Questions

Shares of AzurRx BioPharma reverse split on the morning of Monday, September 13th 2021.The 1-10 reverse split was announced on Monday, September 13th 2021. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 13th 2021. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

AzurRx BioPharma (AZRX) raised $15 million in an initial public offering (IPO) on Friday, September 9th 2016. The company issued 2,100,000 shares at a price of $6.00-$8.00 per share. WallachBeth Capital and Network 1 Financial Securities served as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that AzurRx BioPharma investors own include SCYNEXIS (SCYX), Acasti Pharma (ACST), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

Company Calendar

Today
8/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AZRX
CIK
1604191
Fax
N/A
Employees
12
Year Founded
2014

Profitability

EPS (Trailing Twelve Months)
($11.50)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$32.67 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-482.96%
Return on Assets
-258.47%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.33
Quick Ratio
1.33

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.76) per share
Price / Book
-2.83

Miscellaneous

Outstanding Shares
9,326,000
Free Float
8,645,000
Market Cap
$20.05 million
Optionable
Not Optionable
Beta
1.51

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:AZRX) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners